Ophthalmology Drugs Market to Reach $26.28 Billion by 2030—Vision Care Becomes a Strategic Growth Pillar | MarketsandMarkets™.

Delray Beach, FL, July 07, 2025 (GLOBE NEWSWIRE) -- What’s powering a $26.28 billion opportunity?
The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected to advance at a resilient CAGR of 6.1% from 2025 to 2030, culminating in a forecasted valuation of US$26.28 billion by the end of the period. This momentum is driven by a rising global burden of eye diseases, a strong pipeline of biologics and monoclonal therapies, and major innovation investments. For executives, this is more than a pharmaceutical trend—it's a high-growth sector demanding strategic action now.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132608438

Why is ophthalmology turning into a high-return drug category?
From AMD to DME, the demand for ophthalmic therapies is surging—and intravitreal injections have become the cornerstone of treatment. Blockbuster drugs like aflibercept (Eylea), Faricimab, and brolucizumab deliver precise, retina-targeted relief with proven efficacy and minimal systemic exposure. Their frequent dosing schedules and favourable reimbursement models create a recurring revenue stream that’s hard to match.

What clinical and commercial problems do these drugs solve?
Biologics and fusion proteins in ophthalmology address multiple bottlenecks—from chronic disease management to treatment adherence and safety. Intravitreal therapies overcome drug delivery limitations, offering local, sustained efficacy for degenerative conditions. And with 25+ FDA approvals in this space, the clinical trust and market confidence are already high. That’s why payors and providers alike are betting big on this class of therapies.

Where are we seeing the next wave of investment and impact?
North America leads with robust R&D infrastructure and strong reimbursement frameworks. However, emerging economies are gaining traction as they expand access to biologics and injectables. The high frequency of retinal diseases, coupled with growing healthcare access in Asia and Latin America, positions these regions as high-potential growth zones.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=132608438

Who’s leading—and how are they defending market share?

Regeneron Pharmaceuticals (US) launched Eylea HD (aflibercept 8 mg) with fewer injections and extended dosing intervals (up to 16 weeks). This innovation, backed by PHOTON and PULSAR trials, fortifies its lead against rising competition like Roche’s Vabysmo.
Bayer AG (Germany) is doubling down on cell & gene therapies via BlueRock Therapeutics. Their stem cell-derived therapy OpCT-001 recently received Fast Track Designation from the FDA—reinforcing Bayer’s long-term commitment to retinal innovation.

Other major players like F. Hoffmann-La Roche AG and Novartis AG are scaling pipelines and biologics portfolios to remain competitive in this lucrative landscape.

What’s the real challenge—and what unlocks market scale?
Off-label drug use, patient non-adherence, and cost justifications continue to hold back full-scale adoption. For visionary leaders, the opportunity lies in addressing these friction points—through educational infrastructure, biosimilar competition strategies, and long-term outcome studies that solidify economic ROI.

So, what should C-level leaders really be asking?
Not “Is ophthalmology worth our attention?”—but rather:
• How can we strengthen our biologics portfolio in eye care?
• What partnerships or licensing deals secure access to future pipeline winners?
• Are we building commercial strategies that account for long treatment cycles and premium pricing models?
• And how do we ensure compliance and adherence to maximize lifetime value per patient?

Final Thought: Vision is Value. Ophthalmology is Opportunity.
In an era of biologic breakthroughs and aging populations, ophthalmology drugs offer repeatable, high-margin value. This market isn't just about curing vision—it's about unlocking a resilient business model in specialty care. Organizations that align now will not only improve patient outcomes—they’ll dominate one of the most lucrative therapeutic verticals of the decade.

Vision care is no longer niche—it’s a strategic imperative.

For more information, Inquire Now!

GLP-1 Analogues Market

Drug Discovery Services Market

Pharmaceutical Drug Delivery Market

Pharmaceutical Contract Manufacturing Market

Get access to the latest updates on Ophthalmology Drugs Companies and Ophthalmology Drugs Market Size

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445,
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: www.marketsandmarkets.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.